This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
3
0
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Barclays analyst Carter Gould downgraded the rating for Bristol-Myers Squibb Company (NYSE:BMY) from Equal-Weight to Underweight and maintained the price target of $41. Bristol-Myers Squibb shares gained 11.4% to settle at $50.45 on Friday. See how other analysts view this stock. See how other analysts view this stock.
- Deutsche Bank analyst Scott Deuschle downgraded General Dynamics Corporation (NYSE:GD) from Buy to Hold and maintained the price target …
Full story available on Benzinga.com
Visited 3 times, 1 visit(s) today
